

DAFTAR PUSTAKA

1. Denton CP, Khanna D. Systemic sclerosis. *The Lancet* 2017;390:1685–99.
2. Firestein GS, Kelley WN. Systemic sclerosis and the scleroderma spectrum disorders. *Kelley's Textbook of Rheumatology*, Saunders/Elsevier; 2009; 1268–373.
3. Adigun R, Goyal A, Hariz A. Systemic Sclerosis. In: StatPearls. Treasure Island (FL). 2024
4. Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. *Best Pract Res Clin Rheumatol*. 2010; 24(6):857-69.
5. Allcock RJ. A study of the prevalence of systemic sclerosis in Northeast England. *Rheumatology*. 2004;43(5):596–602.
6. Hamijoyo L. Profil penderita sklerosis sistemik di Poli Reumatologi RSCM/FK UI dari Januari 2007 – Desember 2008. Tugas Akhir Program PPSK IPD FKUI/RSCM 2009.
7. Bergamasco A, Hartmann N, Wallace L, Verpillat P. epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. *Clinical Epidemiology*. 2019;(11):257–73.
8. Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A european scleroderma trials and research (EUSTAR) analysis. *Annals of the Rheumatic Diseases*. 2019;78(9):1242–8.

9. Nilasari D, Hamijoyo L, Kasjmir YI, Setiyohadi B. Case Report Systemic Sklerosis in Two Generations Family : a Mother and Offspring. Indonesian Journal of Rheumatology. 2009; (1):41–3
10. Schmid M, Grolimund Berset D, Krief P, Zyska Cherix, A, Danuser B, et al. Should systemic sclerosis be recognised as an occupational disease in Switzerland?. Swiss Medical Weekly. 2020
11. Muntyanu A, Milan, R, Rahme, E, LaChance A, Ouchene L, Cormier M, et al. Exposure to silica and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group. *Frontiers in Medicine*, 2020(9).
12. Allanore Y, Simms R, Distler O, Trojanowaska M, Pope J, Denton CP, et al. Systemic sclerosis. *Nat Rev Dis Prim*. 2015
13. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: Evidence that systemic sclerosis is a vascular disease. *Arthritis & Rheumatism*. 2013;65(8):1953–62.
14. Asano Y, Sato S. Vasculopathy in scleroderma. *Seminars in Immunopathology*. 2015;37(5):489–500.
15. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. *Arch Immunol Ther Exp (Warsz)*. 2002; 50:325–31.
16. Sato M, Shegogue D, Gore EA, Smith EA, Trojanowska M, Mcdermott PJ. Role of p38 MAPK in transforming growth factor β stimulation of collagen production by scleroderma and healthy dermal fibroblasts. *Journal of Investigative Dermatology*. 2002;118:704–11.

17. Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon- γ discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. *Journal of Cellular Physiology*.1996;167:290–6.
18. Kalogerou A. Early T cell activation in the skin from patients with systemic sclerosis. *Annals of the Rheumatic Diseases*.2005;64:1233–5.
19. Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. *Annals of the Rheumatic Diseases*. 2016;75(12):2142–9.
20. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. *Arthritis & Rheumatism*. 2004;50(6):1918–27.
21. Mackay F, Schneider P. Cracking the BAFF code. *Nature Reviews Immunology*. 2009;9(7):491–502.
22. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. *Arthritis & Rheumatism*. 2005;54(1):192–201.
23. Thoreau B, Chaigne B, Mouthon L. Role of B-cell in the pathogenesis of systemic sclerosis. *Frontiers in Immunology*. 2022;13.
24. Stifano G, Christmann RB. Macrophage involvement in systemic sclerosis: Do we need more evidence? *Current Rheumatology Reports*. 2015;18(1).

25. O'Reilly S. Toll like receptors in systemic sclerosis: An emerging target. *Immunology Letters*. 2018;195:2–8.
26. Gabrielli A, Avvedimento EV, Krieg . Scleroderma. *N Engl J Med*. 2009; 1989–2003
27. Kavian N, Batteux F. Macro- and microvascular disease in systemic sclerosis. *Vascular Pharmacology*. 2015;71:16–23.
28. Piera-Velazquez S, Mendoza F, Jimenez S. Endothelial to mesenchymal transition (ENDOMT) in the pathogenesis of human fibrotic diseases. *Journal of Clinical Medicine*. 2016;5(4):45.
29. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. *Journal of Scleroderma and Related Disorders*. 2017;2(3):137–52.
30. Kahaleh MB, Fan P-S. Mechanism of serum-mediated endothelial injury in scleroderma: Identification of a granular enzyme in scleroderma skin and Sera. *Clinical Immunology and Immunopathology*. 1997;83(1):32–40.
31. Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). *The Kaohsiung Journal of Medical Sciences*. 2022;38(3):187–95.
32. Suliman Y, Distler O. Novel aspects in the pathophysiology of peripheral vasculopathy in systemic sclerosis. *Current Rheumatology Reviews*. 2014;9(4):237–44.

33. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. *The Journal of Immunology*. 2001;166(12):7556–62.
34. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: A pivotal role for fibroblasts as effector cells. *Arthritis Research & Therapy*. 2013;15(3):215.
35. Hinz B. The myofibroblast: Paradigm for a mechanically active cell. *Journal of Biomechanics*. 2010;43(1):146–55.
36. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. *Nature Reviews Rheumatology*. 2011;8(1):42–54.
37. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. *Rheumatology*. 2006;48
38. Hamijoyo L. Sklerosis Sistemik. *Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI*. Jakarta: Interna Publishing; 2015;3277–286.
39. Bolster M, Silver M, Hochberg C, Silman AJ, Smolen JS, Weinblatt ME et al. *Clinical Feature of Systemic Sklerosis*. Eds. *Rheumatology*. 5th ed. Mosby Elsevier. Philadelphia. 2011:1373–85
40. Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TAJ, Steen VD, et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. *Medicine Baltimore*. 2017;96

41. Devgire V, Hughes M. Raynaud's phenomenon. *British Journal of Hospital Medicine*. 2019;80.11: 658-664.
42. Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribí C, et al. The burden of systemic sclerosis in Switzerland – the swiss systemic sclerosis eustar cohort. *Swiss Medical Weekly*. 2021;151
43. Bobeica C, Niculet E, Craescu M, Parapiru E-L, Musat CL, Dinu C, et al. Crest Syndrome in systemic sclerosis patients – is dystrophic calcinosis a key element to a positive diagnosis?. *Journal of Inflammation Research*. 2022;15:3387–94.
44. Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, et al. Brief report: Pulmonary function tests: High rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. *Arthritis & Rheumatology*. 2015;67(12):3256–61.
45. Asif S, Khan A, Faiq M, Din ZU, Zahoor S, Haroon M. Clinical and serological characteristics of systemic sclerosis: Experience of a tertiary care center in Pakistan. *Arch Rheumatol*. 2021;36(4):587-594
46. Clements P. Management of musculoskeletal involvement in systemic sclerosis. *Current Treatment Options in Rheumatology*. 2016;2(1):61–8.
47. Bruni C, Ross L. Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. *Best Practice & Research Clinical Rheumatology*. 2021;35(3):101668.

48. Gupta R, Bammigatti C, Dinda AK, Marwaha V, Gupta S. Prevalence of renal involvement in Indian patients with systemic sclerosis. *Indian Journal of Medical Sciences*. 2007;61(2):91.
49. Chrabaszcz M, Małyszko J, Sikora M, Alda-Malicka R, Stochmal A, Matuszkiewicz-Rowinska J, et al. Renal involvement in systemic sclerosis: An update. *Kidney and Blood Pressure Research*. 2020;45(4):532–48.
50. Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis. *JCR: Journal of Clinical Rheumatology*. 2018;24(6):328–37.
51. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. Classification criteria for systemic sclerosis: an American college of rheumatology/ European league against rheumatism collaborative initiative. *Ann Rheum Dis*. 2013 Nov;72(11):1747–55
52. Van den Hoogen F, Benz D. Systemic sclerosis (diagnosis, differential diagnosis, evaluation of laboratory tests). In: Hachulla E, Czirjak L, editors. *EULAR Textbook on Systemic Sclerosis*. 1st ed. London: BMJ Publishing; 2013:3–15.
53. Varga J, Lafyatis R. Pathogenesis of Systemic Sklerosis. In : Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Eds. *Rheumatology*. 5th ed. Mosby Elsevier. Philadelphia. 2011:1387–402
54. Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, et al. French recommendations for the management of systemic sclerosis. *Orphanet Journal of Rare Diseases*. 2021;16.

55. Medsger TA, Benedek TG. History of skin thickness assessment and the Rodnan skin thickness scoring method in systemic sclerosis. *Journal of Scleroderma and Related Disorders*. 2019;4(2):83–8.
56. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. *J Rheumatol*. 1995;22(7):1281-5.
57. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *Journal of Scleroderma and Related Disorders*. 2017;2(1):11–8.
58. Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, et al. Diagnostic criteria, Severity Classification and guidelines of systemic sclerosis. *The Journal of Dermatology*. 2018;45(6):633–91.
59. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. *WIREs Developmental Biology*. 2015;4(3):215–66.
60. Yun Y-R, Won JE, Jeon E, Lee S, Kang W, Jo H, et al. Fibroblast growth factors: Biology, function, and application for tissue regeneration. *Journal of Tissue Engineering*. 2010;1(1)
61. Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of Structural Biology. *Nature Reviews Molecular Cell Biology*. 2013;14(3):166–80.

62. Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harbor Perspectives in Biology. 2013;5(6).
63. Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan H-F. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmunity Reviews. 2020;19(12):102584.
64. Otrrock Z, Mahfouz R, Makarem J, Shamseddine A. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells, Molecules, and Diseases. 2007;39(2):212–20.
65. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. Journal of Cell Biology. 1998;141(7):1659–73.
66. Usategui A, del Rey MJ, Pablos JL. Fibroblast abnormalities in the pathogenesis of systemic sclerosis. Expert Review of Clinical Immunology. 2011;7(4):491–8.
67. Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis—a lethal component of systemic sclerosis. Nature Reviews Rheumatology. 2014;10(7):390–402.
68. Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of Endothelins. Medicinal Research Reviews. 1992;12(4):391–421.
69. Barton M, Schiffrin EL. In Memoriam: Pioneer in Clinical Endothelin Research. Life Sciences. 2014;118(2):91–6.

70. Chester AH, Yacoub MH. The role of endothelin-1 in Pulmonary arterial hypertension. *Global Cardiology Science and Practice*. 2014;2014(2):29.
71. Kawanabe Y, Nauli SM. Endothelin. *Cellular and Molecular Life Sciences*. 2010;68(2):195–203.
72. Dagamajalu S, Rex DAB, Gopalakrishnan L, Karthikkeyan G, Gurtoo S, Modi PK, et al. A network map of endothelin mediated signaling pathway. *Journal of Cell Communication and Signaling*. 2020;15(2):277–82.
73. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by Endothelin. *Physiological Reviews*. 2011;91(1):1–77.
74. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. *Cardiovascular Research*. 2007;76(1):8–18.
75. Khimji K, Rockey DC. Endothelin—Biology and disease. *Cellular Signalling*. 2010;22(11):1615–25.
76. Davenport AP. International Union of Pharmacology. Update on endothelin receptor nomenclature. *Pharmacological Reviews*. 2002;54(2):219–26.
77. Sun X, Kumar S, Sharma S, Aggarwal S, Lu Q, Gross C, et al. Endothelin-1 induces a glycolytic switch in pulmonary arterial endothelial cells via the mitochondrial translocation of endothelial nitric oxide synthase. *American Journal of Respiratory Cell and Molecular Biology*. 2014;50(6):1084–95.
78. Mauliūtė M, Rugienė R, Žėkas V, Bagdonaitė L. Association of endothelin-1 and cell surface adhesion molecules levels in patients with systemic sclerosis. *Journal of Laboratory Medicine*. 2020;44(6):343–7.

79. Elisa T, Antonio P, Giuseppe P, Alessandro B, Giuseppe A, Federico C, et al. Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: Relevance to the pathogenesis of systemic sclerosis. *Journal of Immunology Research*. 2015; 1–11.
80. Thakkar V, Patterson KA, Stevens W, Wilson M, Roddy J, Sahhar J et al. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. *Clin Rheumatol*. 2018 Jun;37(6):1563-71
81. Waters CE, Shi-Wen X, Denton CP, Abraham DJ, Pearson JD. Signaling pathways regulating intercellular adhesion molecule 1 expression by endothelin 1: Comparison with interleukin-1beta in normal and scleroderma dermal fibroblasts. *Arthritis Rheum*. 2006
82. Tain YL, Chien NH. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). *MDPI*. 2017; 1 – 20
83. Vilcea A, Dan D, Maria B. The Importance of a New Cardiovascular Risk Factor – Asymmetric Dimethylarginine. *Maedica*. 2020; 15(3). 373 – 5
84. Dooley A, Bruckdorfer KR, Abraham DJ. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. *Cardiol Res Pract*. 2012
85. Ames PRJ, Bucci T, Merashli M, Amaral M, Arcaro A, Gentile F et al. Oxidative/nitrative stress in the pathogenesis of systemic sclerosis: are antioxidants beneficial? *Free Radic Res*. 2018;52(10):1063-82

86. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. *Int J Mol Sci.* 2012;13(10):12315-35
87. Curtiss P, Schwager Z, Lo Sicco K, Franks AG Jr. The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon. *J Eur Acad Dermatol Venereol.* 2019;33(3):497-503
88. Pagkopoulou E, Soulaïdopoulos S, Katsiki N, Malliari A, Loutradis C, Karagiannis A et al. The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study. *Clin Rheumatol.* 2023;42(4):1077-85
89. Pagkopoulou E, Soulaïdopoulos S, Triantafyllidou E, Loutradis C, Malliari A, Kitas GD et al. Asymmetric dimethylarginine correlates with worsening peripheral microangiopathy in systemic sclerosis. *Microvasc Res.* 2023
90. Setiyohadi B. Sklerosis Sistemik. In : *Buku Ajar Ilmu Penyakit Dalam Edisi VI.* Jakarta. Interna Publishing. Pusat Penerbitan Ilmu Penyakit Dalam. 2014: 3277–85
91. Kowalska-Kępczyńska A. Systemic Scleroderma—Definition, Clinical Picture and Laboratory Diagnostics. *J Clin Med.* 2022;11
92. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, et al. Elevated levels of pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis. *Arthritis Rheumatol.* 2015;67(2):498–507

93. Aghaei M, Gharibdost F, Zayeni H, Akhlaghi M, Sedighi S, Rostamian A, et al. Endothelin-1 in systemic sclerosis. *Indian Dermatol Online J.* 2012;3(1):14.
94. Cozzani E, Javor S, Laborai E, Drosera M, Parodi A. Endothelin-1 Levels in Scleroderma Patients: A Pilot Study. *ISRN Dermatol.* 2013 :1–4.
95. Blaise, S, R. Maas, C. Trocme, G.D. Kom, M. Roustit, P.H. Carpentier et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. *The Journal of Rheumatology.* 2010;36: 984–988.
96. Turiel, M., L. Gianturco, C. Ricci, P. Sarzi-Puttini, L. Tomasoni, G. Colonna Vde, P et al. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: A controlled cross-sectional study. *Arthritis Care & Research.* 2013;65: 274–280.
97. Kaldas M, Khanna PP, Furst DE, Clements PJ, Wong WK, Seibold JR, et al. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis-assessment of individual body sites in two large randomized controlled trials. *Rheumatology.* 2009;48(9):1143–6.
98. Lawrence A, Khanna D, Misra R, Aggarwal A. Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis. *Dermatol Online J.* 2006
99. Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and

skin pathology in patients with systemic sclerosis. *Rheumatol (United Kingdom)*. 2016;55(5):891–6

100. Song YH, Zhu YT, Ding J, Zhou FY, Xue JX, Jung JH, et al. Distribution of fibroblast growth factors and their roles in skin fibroblast cell migration. *Mol Med Rep*. 2016;14(4):3336–42.

101. Cozzani E, Javor S, Laborai E, Drosera M, Parodi A. Endothelin-1 Levels in Scleroderma Patients: A Pilot Study. *ISRN Dermatol*. 2013;2013:1–4.

